## RVTY: Revvity, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.63 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: declining volume (57% of avg), momentum weakening (-5.2% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($94.81)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Revvity Inc. $RVTY Shares Acquired by Russell Investments Group Ltd.**
- Source: MarketBeat | 20251205T110025 | Somewhat-Bullish | Relevance: 100%
- Russell Investments Group Ltd. significantly increased its stake in Revvity Inc. (NYSE:RVTY) by 24.4% in the second quarter, now owning 66,771 shares valued at $6.49 million. The company's board has authorized a $1 billion share repurchase program and declared a quarterly dividend of $0.07. Revvity slightly exceeded Q2 earnings expectations and maintains a "Moderate Buy" consensus analyst rating with an average price target of $114.75.

**2. Jim Cramer Highlights That “Revvity’s the Cheapest in the Group”**
- Source: Insider Monkey | 20251204T120400 | Bullish | Relevance: 100%
- Jim Cramer highlighted Revvity, Inc. (NYSE: RVTY) as the "cheapest in the group" among life science companies, noting its recent better-than-expected financial results and raised full-year earnings forecast. The company, which originated from the breakup of PerkinElmer, is currently trading at around 21 times this year's earnings estimates. Revvity provides instruments, reagents, software, and sequencing services crucial for genetic testing, disease screening, and research applications.

**3. Revvity Inc. Stock Underperforms Monday When Compared To Competitors**
- Source: 富途牛牛 | 20251204T042511 | Somewhat-Bearish | Relevance: 100%
- Revvity Inc. (RVTY) stock underperformed on Monday compared to its competitors. The article briefly mentions Unity Software's (U.US) fourth-quarter earnings, stating that its revenue increased 35% year-over-year to $609 million, beating consensus estimates, despite reporting a quarterly loss of 66 cents per share.

**4. Korea Investment CORP Has $6.89 Million Position in Revvity Inc. $RVTY**
- Source: MarketBeat | 20251204T020944 | Bullish | Relevance: 97%
- Korea Investment CORP increased its stake in Revvity Inc. (NYSE:RVTY) by 61.7% in the second quarter, valuing its holding at $6.89 million. Other institutional investors also adjusted their positions, with institutional ownership now at 86.65%. Revvity announced a $1.00 billion share buyback program and a quarterly dividend of $0.07, while analysts maintain a "Moderate Buy" rating with an average target price of $114.75.

**5. VolitionRx (NYSE AMERICAN: VNRX) named sole biomarker partner in €6.3M DETECSEPS sepsis detection program**
- Source: Stock Titan | 20251205T044336 | Neutral | Relevance: 72%
- VolitionRx's Nu.Q® NETs H3.1 assay has been selected as the sole biomarker for DETECSEPS, a French real-world program funded by France 2030 with €6.3 million, aimed at the early detection of sepsis. The assay accurately differentiates sepsis from non-infectious inflammation, correlates with disease severity, and demonstrates superior prognostic power for ICU admission compared to existing scores. This inclusion strengthens Volition's pathway to clinical deployment and offers a significant opportunity in the multi-billion dollar sepsis testing market.

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 72.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- T. Rowe Price Invest: 19.9% (-0.6%)
- Vanguard Group Inc: 11.9% (-4.0%)
- Blackrock Inc.: 8.2% (+4.4%)
- Edgepoint Investment: 7.6% (+26.3%)
- Price (T.Rowe) Assoc: 7.2% (+2.4%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.63 indicates undervaluation relative to growth. Forward P/E 19.0x stretched relative to 8% growth. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.2B |
| Beta | 1.06 |
| 52W Range | $81.36 - $128.29 |
| Short Interest | 7.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.63 |
| Forward P/E | 19.0 |
| Current P/E | 20.5 |
| YoY Growth | 7.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 6.1% to 0.9% (-5.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.1pp (needs >4.0% for momentum thesis). MRS_5 (-2.1%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 3.2% shows strong absolute momentum above own 20MA. Outperforming sector by 3.2pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 57. Volume at 57% of 20MA suggests lack of conviction. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.88% (CS: 62) | Neutral |
| RSI_14 | 57.3 | Neutral |
| MACD Histogram | 0.32 | Bullish |
| vs SMA20 | 1.032x | Above |
| vs SMA50 | 1.066x | Above |
| vs SMA200 | 1.054x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $100.79
- **Stop Loss:** $94.81 (5.9% risk)
- **Target:** $112.75 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 83
- **Position Value:** $8,365.57
- **Portfolio %:** 8.37%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-01-26 (Est: $1.55)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.14 | $1.18 | +3.6% |
| 2025Q2 | $1.14 | $1.18 | +3.4% |
| 2025Q1 | $0.95 | $1.01 | +6.4% |
| 2024Q4 | $1.38 | $1.42 | +3.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*